Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    niño jesús | covid | Spain
Previous Study | Return to List | Next Study

Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19 (MESCEL-COVID19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04366271
Recruitment Status : Recruiting
First Posted : April 28, 2020
Last Update Posted : May 11, 2020
Sponsor:
Collaborator:
Apices Soluciones S.L.
Information provided by (Responsible Party):
Mrs. Laura Aranzasti, Hospital Infantil Universitario Niño Jesús, Madrid, Spain

Tracking Information
First Submitted Date  ICMJE April 23, 2020
First Posted Date  ICMJE April 28, 2020
Last Update Posted Date May 11, 2020
Actual Study Start Date  ICMJE May 7, 2020
Estimated Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 27, 2020)
Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment [ Time Frame: 28 days ]
Percentage of patients death due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 27, 2020)
  • Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment [ Time Frame: 14 days ]
    Percentage of patients death due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment
  • Mortality from any cause at 28 days [ Time Frame: 28 days ]
    Percentage of patients death due to any cause at 28 days of treatment
  • Days without mechanical respirator and without vasopressor treatment for 28 days [ Time Frame: 28 days ]
    Number of days without mechanical respirator and without vasopressor treatment for 28 days
  • Patients alive without mechanical ventilation and without vasopressors on day 28 [ Time Frame: 28 days ]
    Percentage of patients alive without mechanical ventilation and without vasopressors on day 28
  • Patients alive and without mechanical ventilation on day 14 [ Time Frame: 14 days ]
    Percentage of patients alive and without mechanical ventilation on day 14
  • Patients alive and without mechanical ventilation on day 28 [ Time Frame: 28 days ]
    Percentage of patients alive and without mechanical ventilation on day 28
  • Patients alive and without vasopressors on day 28 [ Time Frame: 28 days ]
    Percentage of patients alive and without vasopressors on day 28
  • Days without vasopressors for 28 days [ Time Frame: 28 days ]
    Number of days without vasopressors for 28 days
  • Patients cured at 15 days [ Time Frame: 15 days ]
    Percentage of patients cured at 15 days
  • Incidence of Treatment-Emergent Adverse Events [ Time Frame: 1 year ]
    Percentage of patients with each adverse event
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19
Official Title  ICMJE Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19
Brief Summary

The disease caused by the SARS-CoV-2 virus is a viral disease that infects the lungs, producing flu-like symptoms. Elderly infected patients and/or those with co-morbidities may suffer from acute respiratory distress syndrome due to pneumonia (COVID-19 disease). Given the high transmission, this virus has spread in recent months from Wuhan (China) to the whole world, becoming a global emergency pandemic. The lack of curative treatment for this disease justifies the need to carry out clinical trials that provide quality evidence on treatment options. Given the pathophysiology of the disease, which involves an uncontrolled inflammatory response of alveolar cells, a treatment that attenuates the cytokine cascade could be key in rescuing the patient's lung tissue. Mesenchymal cells, due to their immunoregulatory potential and regenerative capacity, can be an effective treatment for patients infected with the SARS-CoV-2 virus.

In the present study we propose a therapy with undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue, a treatment whose safety has already been described in other clinical trials and that shows promising results in pilot studies carried out in China.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE COVID
Intervention  ICMJE
  • Biological: Mesenchymal cells
    1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
  • Drug: Standard of care
    Best treatment option for COVID-19 according to investigator criteria
Study Arms  ICMJE
  • Experimental: Mesenchymal cells
    Undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
    Intervention: Biological: Mesenchymal cells
  • Active Comparator: Standard of care
    Standard of care
    Intervention: Drug: Standard of care
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 27, 2020)
106
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 31, 2021
Estimated Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients aged between 40 and 80 years
  2. Body weight between 50 kg and 100 kg
  3. PCR diagnosis of SARS-CoV-2 virus infection
  4. Clinical diagnosis of severe lung involvement associated with SARSCoV- 2 virus infection according to the criteria of the National Health Commission of China, that is, patients who meet at least one of the following criteria:

    1. Respiratory distress with ≥ 30 breaths per minute; or
    2. Oxygen saturation ≤ 93% at baseline; or
    3. Partial arterial oxygen pressure (PaO2) / Fraction of inspiration of O2 (FiO2) ≤300mmHg. (PaO2 / FiO2 is accepted based on SatO2). Patients who do not require respiratory support, or who require noninvasive respiratory support (conventional, high-flow oxygen therapy, or non-invasive mechanical ventilation) are considered eligible.
  5. Patients who are already receiving the standard medical treatment available for severe lung involvement associated with SARS-CoV-2 virus infection or any of the standard treatments are contraindicated in the patient and cannot be used and it is necessary to consider other alternatives.
  6. Women who are surgically sterile or postmenopausal or women of childbearing potential with negative urine or serum pregnancy test or men willing to use condoms for the entire duration of the study or for three months after the last dose of the investigational drug, whichever is later, or have a partner who is using a contraceptive method with high efficacy, such as described above.
  7. Signed informed consent.

Exclusion Criteria:

  1. Clinical diagnosis of critically serious lung involvement associated with SARS-CoV-2 virus infection according to the criteria of the National Health Commission of China, that is, patients who meet any of the following criteria:

    1. Respiratory failure requiring invasive mechanical ventilation; or
    2. Shock; or
    3. Combination with failure of another organ; need for ICU admission for monitoring / treatment.
  2. Patients who are expected to develop rapidly fatal disease within 72 hours of enrollment.
  3. Inability to maintain a mean arterial pressure > 50 mmHg before selection despite the presence of vasopressors and intravenous fluids.
  4. Patients requiring treatment with vasopressors (dopamine > 5 mg / kg / min or any dose of epinephrine, norepinephrine, phenylephrine, or vasopressin) for at least 2 hours to maintain systolic blood pressure (SBP) > 90 mmHg (or mean blood pressure [MBP] > 70 mmHg) after adequate fluid administration.
  5. Patients who are not expected to live more than 3 months due to other medical illnesses, such as neoplasia or other terminal illnesses.
  6. Patients with primary or metastatic lung cancer or with chemotherapy scheduled for the next 90 days.
  7. Patients with a known primary immunodeficiency disorder or with acquired immunodeficiency syndrome (HIV infection) with a CD4 count <200 cells / mm3 or who do not have an undetectable viral load (<200 copies).
  8. Patients receiving immunosuppressive therapy (including chronic treatment with any alpha antitumor necrosis factor [TNFa]) or corticosteroid therapy.
  9. Granulocytopenia, not due to sepsis, evidenced by an absolute neutrophil count <500 per μL.
  10. Hematologic or lympho-reticular malignancies, unless in remission.
  11. Patients who have received a stem cell, organ, or bone marrow transplant in the last 6 months.
  12. Patients in current treatment with a biological product (eg, antibodies, cell therapy) or with plasmapheresis in the last 8 weeks.
  13. Patients who are currently receiving or have received another investigational drug in the 90 days prior to study initiation (or 5 halflives of the investigational compound, whichever is longer).
  14. Known allergies or hypersensitivity to antibiotics and/or any component of the investigational product.
  15. Patients with known severe liver function impairment.
  16. Patients with known severe kidney function impairment.
  17. Patients admitted in the previous 15 days for causes other than SARS-CoV-2 virus infection.
  18. Diseases other than SARS-CoV-2 virus infection leading to New York Heart Association class IV status.
  19. Terminal neuromuscular disorders that alter the gradual withdrawal of the ventilator (eg, amyotrophic lateral sclerosis).
  20. Patients with complete tetraplegia (traumatic or otherwise).
  21. Dementia-Alzheimer and another situation in which is considered patient can not understand what is explaining, can not read or does not understand the language.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 40 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Luis Madero, MD +34 915035900 ext 258 luis.madero@salud.madrid.org
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04366271
Other Study ID Numbers  ICMJE MESCEL-COVID19
2020-001450-22 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Mrs. Laura Aranzasti, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Study Sponsor  ICMJE Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Collaborators  ICMJE Apices Soluciones S.L.
Investigators  ICMJE
Study Chair: Luis Madero, MD Hospital Infantil Universitario Niño Jesús, Oncohematology Department
PRS Account Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP